Aralia

Other Names

American SpikenardAngelica TreeAralia apioidesAralia armataAralia atropurpureaAralia bicrenataAralia cachemiricaAralia californicaAralia chinensisAralia continentalisAralia cordataAralia dasyphyllaAralia echinocaulisAralia elataAralia familyAralia fargesiiAralia feroxAralia finlaysonianaAralia foliolosaAralia glabraAralia hispidaAralia humilisAralia hypoglaucaAralia malabaricaAralia nudicaulisAralia parasiticaAralia racemosaAralia schmidtiiAralia spinifoliaAralia spinosaAralia stipulataAralia subcordataAralia thomsoniiAralia tibetanaAralia tomentellaAralia undulataAralia urticifoliaAralia yunnanensisAraliaceaeBristly SarsaparillaBristly SarsparillaCalifornia SpikenardDevil's Walking StickDimorphanthus elatusDwarf ElderFalse SarsaparillaFalse SpikenardFool's SangHercules' ClubHungry RootIndian RootJapanese Angelica TreeLife-of-ManOld Man's RootPetty MorelPetty-MorrelPettymorrelRabbit RootShot BushSmall SpikenardSpice BerrySpiceberrySpignetSpikenardWild LiquoriceWild Sarsaparilla

Synopsis

Aralia: Botanical Identity, Traditional Uses, Phytochemistry, and Scientific Evidence

1. Identity and Botanical Classification

Aralia is a genus of flowering plants in the family Araliaceae — the same family that includes Panax (ginseng), Eleutherococcus (Siberian ginseng), and Hedera (ivy). Araliaceae is a large family containing 50 genera and 1,412 species; the genus Aralia itself contains approximately 71 species, many of which are used as montane food and traditional medicine in Eurasian countries. In the context of dietary supplementation and traditional medicine, several species are of primary importance:

Aralia elata (Miq.) Seem. — Also known taxonomically as Aralia elata var. mandshurica (Rupr. & Maxim.) J.Wen, or Aralia mandshurica Rupr. & Maxim. Common names include Manchurian thorn tree, Japanese angelica tree, and Longya Aralia chinensis L. This is the species most thoroughly studied pharmacologically and the one with official pharmacopeial status in Russia.
Aralia continentalis Kitag. — Known in Korean as Dok-hwal (독활). A perennial herb distributed across East Asia, distinct from the tree-form species.
Aralia racemosa L. — American spikenard. A native North American herbaceous perennial with a distinct tradition of indigenous use.
Aralia taibaiensis — A Chinese species distributed in the Qinba Mountains of western China, used traditionally as a folk medicine for diabetes.

Aralia mandshurica (also named Aralia elata) is a member of the Araliaceae family; it is native to the eastern regions of Russia, northern China, and Korea, and is an upright deciduous small tree or shrub growing up to 6 m in height. Aralia racemosa (American spikenard) is a rhizomatous, herbaceous perennial also belonging to the Araliaceae family, characterized by its shrubby appearance, soft stems, and height of 3 to 5 feet (occasionally up to 10 feet).

1.1 Plant Parts Used and Common Preparations

Aralia species are mainly used in root, stem, and bark as medicine, and traditionally these parts are used to treat rheumatic arthralgia, soreness of the waist and knees, traumatic injury, lumps, abscesses, and other diseases. The leaves, bark, and root cortexes of A. elata have been commonly used in traditional folk medicine in China for the treatment of various diseases, such as neurasthenia, rheumatoid arthritis, diabetes mellitus, gastrospasm, constipation, and hepatitis. Besides medicinal applications, the young shoots of A. elata are a popular edible plant, particularly during springtime.

Common preparatory forms include:

Alcoholic tincture (Tinctura Araliae): The ethanol (70%) tincture (1:5) has been available since 1967 and is standardized to a minimum of 0.5% of the sum of aralosides A, B, and C.
Tablets ("Saparal"): Since 1975, Saparal tablets containing a mixture of ammonium salts of aralosides A, B, and C (0.05 g) have been on the market in the USSR/Russia.
Herbal species ("Arfazetin"): Arfazetin is a mixture of different plant species including root of Aralia (15%) and is recommended as a hypoglycemic preparation.
Decoctions and infusions: Used traditionally in Russia, China, Korea, Japan, and North America, prepared from roots, bark, and leaves.
Dry extracts and powders for encapsulation, used in modern supplement markets.

2. Traditional and Historical Use

2.1 East Asian Traditions

Aralia has a long history of medicinal use in China; the earliest records of medicinal usage of the genus could be traced back to the Qian Jin Fang (千金方), written by Simiao Sun in the early Tang Dynasty (A.D. 7th century). The treatment of rheumatism is a common traditional effect of all medicinal Aralia; it is often used in clinical treatment of rheumatoid arthritis, rheumatic arthritis, and other diseases.

In Japan, the commonly used medicinal species of Aralia is A. elata, which is called "Taranoki (たらのき)." The buds of Aralia elata (Japanese angelica tree) have long been used as a tonic, antiarthritic, and antidiabetic agent in China and Japan.

In Korea, A. continentalis, known as "Dok-hwal (독활)," is mainly grown as a vegetable, and its dried roots are traditionally used to treat joint pain, rheumatism, low back pain, and trauma.

2.2 Russian and Siberian Traditions

In Russia, the significant interest in Aralia arises from results of ethnopharmacological investigations in the Far East region, where Aralia roots were used for treating tonsillitis, cold, flu, and stomatitis; as a light diuretic; and for treating bed-wetting. The Nanai, a Tungusic people of the Russian Far East, have used the roots of Aralia elata for toothache and stomatitis, as a tonic, and for treatment of liver diseases. The Ainu, aboriginal peoples who once dominated Hokkaido in Japan, have used the roots of Aralia elata as a stomachic.

While A. elata is often considered an example of a medicinal plant used in Chinese, Korean, and Japanese traditional medicine, the contemporary applications of Aralia in officinal medicine result primarily from a large number of pharmacological and clinical investigations carried out in the former USSR in the mid-20th century. Since the 1950s, medicinal preparations from radices of A. elata and radices of A. mandshurica have secured an established position within Russian/USSR medicine, as evidenced by the inclusion of the drug in recent editions of the National Pharmacopoeia of the USSR and in the Register of Medicinal Preparations of Russia. In Russian codified medicine, Aralia belongs to the group of so-called "classical adaptogens."

2.3 North American Traditions (Aralia racemosa)

Various parts, and primarily the roots, of Aralia racemosa have traditional medicinal use among the Algonquin, Cherokee, Chippewa, Choctaw, Iroquois, Malicite, Menominee, Meskwaki, Micmac, Ojibwe, Penobscot, and Potawatomi Indigenous groups of the eastern and Midwestern parts of the USA. Native Americans used an infusion of the roots to treat a wide variety of ailments, including tuberculosis, coughs, colds, sore throats, menstrual problems, kidney problems, and lung diseases, and they also applied a poultice of the root to burns, swelling, wounds, boils, sprained muscles, and broken bones.

The Cherokee prepared a root infusion as a wash to alleviate back pain and rheumatism and also used it in teas to treat headaches; the Shawnee employed root teas to address coughs, chest pains, asthma, and stomach gas pains; the Iroquois used a compound decoction of roots and bark as a blood purifier for conditions involving watery blood.

Early European settlers, upon observing indigenous peoples' use of spikenard, began to adopt it into their own medicinal practices; this transition marked the beginning of a broader integration of Native American herbal knowledge into Eclectic medicine, which sought to combine various healing traditions. As the years progressed, Appalachian folk herbalists also embraced American spikenard. At one time it was widely used as a substitute for the tropical medicinal herb sarsaparilla.

3. Key Constituents and Active Compounds

More than 290 chemical constituents have been isolated from the genus Aralia, including triterpenoid saponins, terpenoids, organic acids, flavonoids, polyacetylenes, phenylpropanoids, and other constituents. Up to now, more than two hundred compounds have been isolated from the genus, including triterpenoid saponins, terpenoids, organic acids and their esters, flavonoids, polyacetylenes, phenylpropanoids, and others; triterpenoid saponins and terpenoids are the two predominant types present in high content in Aralia.

3.1 Triterpenoid Saponins (Araliosides / Aralosides)

Eight compounds have been isolated from the root bark of Aralia elata, identified by physicochemical and spectral analysis; they include araloside A, araloside C, chikusetusaponin Ib, acanthoside D, and silphioside A, and a new natural product was named araloside A methyl-ester. An additional new compound, 3-O-beta-D-glucopyranosyl oleanolic acid-28-O-beta-D-glucopyranoside, was named araloside G.

The genus Aralia contains many plants used medicinally in Asia and the Americas, but although many members are used medicinally, the vast majority of the genus has not been explored chemically; the species that have been explored chemically have yielded compounds including triterpenoid saponins, sterols, diterpenoids, and acetylenic lipids.

The principal pharmacologically characterized saponins include:

Aralosides A, B, and C — the standardization markers for official Russian pharmaceutical preparations; aralosides A, B, and C stimulate the central nervous and immune systems, possess anti-stress properties, and protect against unfavorable environmental conditions such as hypoxia or viral infections.
Elatoside C — a major triterpenoid compound. Elatoside C is one of the major triterpenoid compounds isolated from Aralia elata that is known to be cardioprotective.
Araloside C (AsC) — Araloside C is a cardioprotective triterpenoid compound mainly isolated from Aralia elata.
Congmuyanosides A, C, D — triterpenoids isolated from the buds.
Echinocystic acid and hederagenin derivatives — also identified from buds and leaves.
Tarasaponin IV and elatoside L — newer oleanane-type triterpene saponins isolated from bark. Oleanane-type triterpene saponins are the main component of A. elata.

Tentative identification in leaf extracts of A. elata has revealed the presence of 14 saponins and nine phenolic compounds. Specific compounds such as chlorogenic acid, isochlorogenic acid A, and quercitrin have emerged as marker compounds for distinguishing samples from different regions.

3.2 Diterpenoids

One hundred and fifty-nine compounds have been isolated and identified from A. continentalis, encompassing diterpenoids, steroids, triterpenoids, volatile components, phenolics, vitamins, trace elements, and other compounds. Three compounds extracted from A. continentalis — acanthoic acid, continentalic acid, and kaurenoic acid — are the primary diterpenoids identified by NMR analysis. The major secondary metabolites, continentalic acid and kaurenoic acid, exhibit antibacterial activity against several bacteria including S. mutans, Staphylococcus aureus, Enterococcus strains, and Porphyromonas gingivalis.

3.3 Flavonoids and Phenolic Compounds

The leaves of A. elata mainly contain triterpene saponins, flavonoids, alkaloids, polysaccharides, mineral elements, and amino acids. Saponins and flavonoids are the main bioactive components in its leaves.

3.4 Polysaccharides and Other Compounds

Pharmacological effects of Aralia elata are related to the presence of over 150 secondary metabolites, including flavonoids, sterols, polysaccharides, terpenoid saponins, and terpenoid acids. Polysaccharides from A. elata have been investigated for cardiovascular protective properties in preclinical models.

4. Mechanisms of Action

4.1 Adaptogenic / Stress-Protective Mechanisms

Pharmacological studies on animals have shown that Aralia increases physical working capacity and affords a stress-protective effect against a broad spectrum of harmful factors including cold stress, immobilization, UV irradiation, and low air pressure. The phytoadaptogen exerts an effect on the central nervous, reproductive, immune, respiratory, and gastrointestinal systems; the metabolic syndrome including hypolipidemic and antidiabetic effects; and blood coagulation.

4.2 Cardiovascular and Anti-Arrhythmic Mechanisms

The total saponins of Aralia elata (TAS) stimulate heart activity, possess anti-myocardial ischaemic and anti-hypoxic activities, exhibit a strong anti-arrhythmic effect, and exert protective effects against diabetic cardiomyopathy. TAS exert cytoprotective effects by inhibiting TNF-α-triggered endothelial cell apoptosis, mitochondrial membrane potential depolarisation, and the regulation of inflammatory factors (IL-6, MCP-1, and VCAM-1) while suppressing NF-κB transcription; this phenomenon is related to activation of the PI3K/Akt signalling pathway.

Elatoside C derived from Aralia elata shows cardioprotective activity in ischemia/reperfusion-induced apoptosis through attenuation of ER stress and increased phosphorylation of STAT3. At 25 μM, elatoside C treatment provided significant protection against hypoxia/reoxygenation-induced H9c2 cardiomyocyte cell death, as evidenced by improved cell viability, maintained mitochondrial membrane potential, diminished mitochondrial ROS, and reduced apoptotic cardiomyocytes (P < 0.05).

Araloside C (12.5 μM) pretreatment for 12 hours significantly suppressed hypoxia/reoxygenation injury in H9c2 cardiomyocytes, including improving cell viability, attenuating LDH leakage, and preventing cardiomyocyte apoptosis; it also inhibited H/R-induced ER stress by reducing the activation of ER stress pathways (PERK/eIF2α and ATF6) and decreasing the expression of ER stress-related apoptotic proteins (CHOP and caspase-12).

4.3 Anti-Inflammatory Mechanisms

Studies on isolated organs, cells, and enzymes have revealed that Aralia preparations exhibit antioxidant activities and enhance sarcoplasmic reticulum Ca²⁺-ATPase activity, inhibit endoplasmic reticulum stress-associated apoptosis markers (GRP78, CHOP, Caspase-12, and JNK), and increase phosphorylation of STAT3 and Bcl2/Bax ratio; they also show cytotoxic activities against some tumor cell lines; affect NF-κB and PPARs activities; and regulate biosynthesis of pro-inflammatory cytokines and inflammation-related protein expression, tissue respiration, and oxygen consumption.

In HepG2 cells using a luciferase reporter system, oleanane-type triterpene saponins from the bark of A. elata were measured for their inhibition of NF-κB and activation of PPARs activities; elatoside L (compound 2) and kalopanax-saponin F (compound 4) were found to inhibit NF-κB activation stimulated by TNF-α in a dose-dependent manner, with IC₅₀ values of 4.1 and 9.5 μM, respectively.

4.4 Antidiabetic and Antioxidant Mechanisms

The antidiabetic activity of the extract of root bark of Aralia taibaiensis has been demonstrated to correlate with its combined antioxidant and antiglycation properties; to confirm further the constituents responsible, 12 triterpenoid saponins were isolated from the extract and examined for their antioxidant and antiglycation activities. Aralia taibaiensis root bark extract has long been used in China as a folk medicine for the treatment of diabetes, and its main active ingredient is the triterpene saponin; it has been shown to have antioxidant, antihyperglycaemic, and antihyperlipidaemic effects.

4.5 Anti-Inflammatory Mechanisms in A. continentalis

Diterpenoids, steroids, triterpenoids, volatile components, and phenolics from A. continentalis have exhibited pronounced pharmacological effects, including anti-inflammatory, analgesic, antioxidant, hepatoprotective, antidiabetic, and antimicrobial activities. When S. mutans was exposed to individual or mixed fractions of diterpenoids, severe growth defects and unique morphology were observed; the proportion of unsaturated fatty acids in the cell membrane was increased compared to that of saturated fatty acids in the presence of diterpenoids.

5. Scientific Evidence by Area of Use

5.1 Adaptogenic Activity and Physical/Mental Performance

Evidence level: Predominantly preclinical (animal studies) with some human clinical data from Russian trials, mostly not available in peer-reviewed English-language literature.

Throughout the extensive body of scientific research published in the literature, a consistent theme emerges regarding the effectiveness of Aralia as an adaptogen offering generalized resistance to stressors; together with the general properties of phytoadaptogens, Aralia has its own specificity, which manifests in cardioprotective and antiarrhythmic effects; and almost all effects of Aralia described in traditional medicine and claimed in official medicine of the USSR/Russia are supported with scientific evidence and clinical data.

In healthy subjects, Aralia has been reported to increase mental performance, working capacity, and endurance of movement. After swimmers trained while taking Saparal at the dose of 50 mg/day for 35 days, a variety of effects was observed: the level of tissue hypoxia decreased after physical loading due to an increase in the level of oxidation-reduction processes in the tissue, the protective properties of an organism were promoted, and the cytophagous activity of leukocytes was increased; additionally, the decrease in work capacity during the first two to three days after high physical loading was also reduced.

Promising stress-relieving effects of Aralia are reported for professionals whose work requires a high level of attention, and its proposed ability to moderate stress-induced damage and dysfunction in the cardiovascular tissue might make Aralia the adaptogen of choice among patients with higher risk for cardiovascular diseases.

An important limitation is that although limited studies on specific properties of Aralia are available in English in various reviews of medicinal plants and adaptogens, an enormous amount of detailed information contained in a number of key articles in Russian remains relatively inaccessible to Western scientists. The majority of clinical data originates from Soviet-era research and has not been replicated in modern randomized controlled trials meeting current standards of evidence.

5.2 Neurological and Asthenic Conditions

Evidence level: Clinical data from USSR/Russian trials, not independently replicated in modern controlled studies.

Numerous clinical trials have shown the efficiency of Aralia preparations in patients with traumatic brain injury (accompanied with asthenic syndrome and neurotic reactions, depression, neurasthenia, and psychasthenia), neurological diseases (accompanied with astheno-depressive and astheno-hypochondriasis syndromes). Clinical trials have also shown efficiency in patients with myasthenia syndrome accompanied by chronic post-influenza arachnoiditis, and arterial hypotension. These findings are primarily derived from Soviet and Russian institutional literature; independent replication in rigorously designed randomized controlled trials published in international peer-reviewed journals is lacking.

5.3 Cardiovascular System

Evidence level: Preclinical (in vitro and animal), no published human clinical trials specifically for cardiovascular endpoints.

Together with general properties of adaptogens, Aralia has its own specificity, which manifests in cardioprotective and antiarrhythmic activities. The most characterized mechanisms involve elatoside C and total saponin fractions acting on cardiomyocytes. The total saponins of A. elata stimulate heart activity, possess anti-myocardial ischaemic and anti-hypoxic activities, exhibit a strong anti-arrhythmic effect, and exert protective effects against diabetic cardiomyopathy. All current cardiovascular evidence is based on cell culture and animal models; no prospective human clinical trials on cardiovascular endpoints have been published in indexed English-language literature.

5.4 Metabolic Syndrome, Glycemic Regulation, and Lipid Metabolism

Evidence level: Preclinical (in vitro, animal); one cited human study combination with another plant extract.

Aralia extract administration appears to affect plasma glucose level and hepatic lipid accumulation and ameliorate hyperinsulinemia. A synergistic antiobesity effect was reported for the combination of A. mandshurica and Engelhardtia chrysolepis extracts, and an antidiabetic effect for the combination of Aralia and glipizide. The interaction with glipizide, a sulfonylurea antidiabetic drug, raises the pharmacodynamic interaction concern that Aralia may potentiate hypoglycemic agents.

Aralia taibaiensis is a natural medicinal and food plant rich in triterpenoid saponins with hypoglycaemic, antioxidant, hepatoprotective, anti-gastric ulcer, and anti-inflammatory effects; one study investigated the antioxidant, anti-aging, and organ protective effects of total saponins from A. taibaiensis (TSAT) in D-galactose-induced aging rats. In vitro experiments showed that TSAT had a scavenging effect on DPPH, ABTS, hydroxyl radicals, and superoxide radicals in a dose-dependent manner. These are animal and in vitro findings; human clinical trials on glycemic control with Aralia mono-preparations are not available in current indexed literature.

5.5 Anti-Inflammatory and Analgesic Effects

Evidence level: In vitro and animal models; no published human clinical trials.

Pharmacological studies have shown that various extracts and compounds isolated from different parts of Aralia plants possess a wide range of biological activities including anti-inflammation, analgesic, anti-tumor, liver protection, protection of cardiovascular and nervous systems, regulating substance metabolism, antioxidation, antibacterial, and antiviral effects; among them, saponins and diterpenoids have been deeply studied in anti-inflammation, anti-tumor, and liver protection.

Alcohol extract of A. continentalis reduced pain sensitivity of the ankle joint induced by Freund adjuvant injection and produced an analgesic effect in preclinical animal experiments. Congmuyanoside A, echinocystic acid, and 3-O-glucopyranosyl-hederagenin suppressed superoxide generation induced by N-formyl-methionyl-leucyl-phenylalanine (fMLP) in human neutrophils in a concentration-dependent manner; congmuyanosides C, D, and echinocystic acid significantly suppressed superoxide generation induced by phorbol myristate acetate (PMA) and arachidonic acid. These findings are from isolated cell studies.

5.6 Antitumor and Cytotoxic Activity

Evidence level: In vitro and animal models only; no clinical evidence in humans.

Aralia elata has long been used as a tonic, anticancer, and antidiabetic agent in China and Japan, and is widely consumed as food. Total saponins extracted from leaves of A. elata have been reported to possess significant antitumor effect on human breast cancer in vivo and in vitro. These findings are limited to preclinical laboratory models and cannot be extrapolated to human oncology applications at this stage.

5.7 Antiviral and Immunomodulatory Activity

Evidence level: Limited clinical observation; no modern controlled trials.

Aralia tincture and "Saparal" are claimed to be useful as antiviral remedies; radioprotective properties of Aralia have been reported in pregnant women. These claims originate from Soviet-era clinical observation records and are not confirmed in modern controlled studies.

5.8 Cognitive Function and Post-Traumatic Stress

Evidence level: Animal model only for PTSD application.

The ethanol extract of Aralia continentalis is traditionally used in Oriental medicine and has been shown to possess pharmacological properties including anti-inflammatory, anti-cancer, anti-atherosclerotic, and anti-diabetic effects; however, the effects of the extract on cognitive memory and its mechanism of action in PTSD remained unclear, prompting investigation of its effect on the spatial cognitive impairment caused by single prolonged stress in a rat model of PTSD.

5.9 Antibacterial Activity

Evidence level: In vitro studies.

Effective antibacterial substances of Aralia continentalis have anti-biofilm and bactericidal activity against the oral pathogen Streptococcus mutans; three compounds — acanthoic acid, continentalic acid, and kaurenoic acid — were identified by NMR and investigated for their effects on the physiology of S. mutans; when exposed to individual or mixed fractions of these diterpenoids, severe growth defects and unique morphology in S. mutans were observed.

6. Body Systems and Health Areas of Association

The phytoadaptogen exerts an effect on the central nervous, reproductive, immune, respiratory, and gastrointestinal systems; the metabolic syndrome including hypolipidemic and antidiabetic effects; and blood coagulation. Based on the compiled preclinical and clinical research, the main body systems associated with Aralia include:

Central and peripheral nervous system: Adaptogenic/stimulant effects; application in asthenia, depression, neurasthenia, and traumatic brain injury recovery (Russian clinical record).
Cardiovascular system: Cardioprotective, anti-arrhythmic, anti-ischaemic, and vascular endothelial protective effects (primarily preclinical).
Metabolic/endocrine: Hypoglycemic, antihyperlipidemic, and anti-obesity effects (preclinical; limited human data).
Immune system: Immunostimulant, antiviral, and anti-infective activity (preclinical; some clinical observation).
Musculoskeletal: Antirheumatic and analgesic (traditional use and animal models).
Liver/hepatic: Hepatoprotective activity documented in preclinical studies across multiple species.
Respiratory: Traditional use as expectorant and for respiratory infections (A. racemosa).
Oral/antimicrobial: Anti-biofilm and antibacterial actions against oral pathogens (A. continentalis diterpenoids, in vitro).

7. Dosage Forms and Dosages Reported in Sources

The following dosages are reported in source literature and apply primarily to preparations of Aralia elata / A. mandshurica as used in Russian officinal medicine:

Tinctura Araliae (70% ethanol tincture, 1:5): The tincture is available in pharmacies in Russia by prescription and is recommended for internal administration at the dose of 0.75–1.0 ml, twice a day. Aralia tincture is available in Russia in pharmacies by prescription and recommended at the dose of 30–40 drops, 2–3 times a day, for 10–15 days for use as a CNS stimulant and as an adaptogen.
Saparal tablets: Each Saparal tablet contains 0.05 g of a mixture of ammonium salts of aralosides A, B, and C; "Saparal" is prescribed for internal administration at the dose of 1 tablet twice a day (preferably in morning and afternoon) for 15–30 days.
Athletic performance study (Saparal): After swimmers trained while taking Saparal at the dose of 50 mg/day for 35 days, decreases in tissue hypoxia and improvements in leukocyte cytophagous activity were observed.

No standardized dosage recommendations for Aralia racemosa or A. continentalis in the form of dietary supplements are established in indexed literature. No human clinical trial dosing data for these species is available in current peer-reviewed sources.

8. Safety, Toxicology, and Drug Interactions

8.1 General Safety Record

Many unpublished scientific reports were deposited in the regulatory archive of the Ministry of Public Health and are not available to the public; however, no side effects have been reported in the clinical trials and no public reports or articles about toxicity of Aralia preparations for humans were published during the more than 47 years of drug monitoring in the USSR/Russia. Modern approaches in mechanisms of action, including the study of gene expression profiling, adverse effects, potential interactions with standard-of-care medications, and active compounds, are still limited and suggest the most up-to-date challenges for future research of A. elata.

8.2 Preclinical Toxicology

Oral administration of the ethanol leaves extract (ELE) at a dose of 540 mg/kg is considered safe in rats without severe toxic effects; however, the safety of ELE in humans needs further investigation, and additional toxicological data should be collected and confirmed over repeated long-term studies.

Toxicity research is of great significance for clinical drug safety evaluation; there are few toxicological studies on Aralia species at present, and further studies are still needed. On mice, during acute peroral delivery of alcohol tincture (70%), the LD₅₀ was determined to equal 1.25 g/kg.

Phytochemical studies showed that plants with complex mixtures of saponins, flavonoids, and alkaloids caused an increased risk of adverse reactions or synergistic effects of chemical interactions. This is a general mechanistic caution applicable to complex herbal preparations.

8.3 Drug Interactions

Aralia antagonizes CNS depressants (including barbiturates, tranquilizers, and anticonvulsants) and hypnotics; it is not recommended to take Aralia tincture in the evening hours in order to avoid sleep disturbances.

A synergistic antidiabetic effect for the combination of Aralia and glipizide has been reported, which implies a potential additive or synergistic hypoglycemic interaction when co-administered with antidiabetic medications; this warrants caution in persons using insulin or oral hypoglycemic agents.

Because Aralia extract administration appears to affect plasma glucose level and hepatic lipid accumulation and ameliorate hyperinsulinemia, it might provide benefits — but also interactions — for patients with obesity and diabetes.

8.4 Stimulant Properties and Timing

Saparal is prescribed for internal administration at the dose of 1 tablet twice a day, preferably in morning and afternoon; both tincture and tablets in Russia are claimed as tonic. The CNS-stimulating nature of Aralia preparations means that administration in evening hours may disrupt sleep.

8.5 Limitations of Safety Data

Toxicity research is of great significance for clinical drug safety evaluation; there are few toxicological studies on Aralia species at present, and further studies are still needed. Long-term human safety data beyond the observational USSR/Russian clinical record are absent from the indexed scientific literature. The safety of Aralia in pregnancy, lactation, pediatric populations, and in the context of specific comorbidities has not been formally established in controlled studies.

9. Evidence Strength Summary

Adaptogenic / CNS-stimulating / anti-asthenic effects: Supported by USSR/Russian clinical trials accumulated over decades of official pharmacopeial use, but these are largely non-indexed, non-English, and not replicated by modern randomized controlled trials. Preclinical evidence (animal) is substantial.
Cardiovascular (cardioprotective, anti-arrhythmic, endothelial): Strong preclinical (in vitro and animal) evidence; no human clinical trial data in indexed literature.
Anti-inflammatory and analgesic: In vitro and animal data with defined molecular targets (NF-κB, PPARs, neutrophil oxidative burst); no human trials.
Antidiabetic / metabolic: Preclinical and limited human observational data; interaction with glipizide noted; formal clinical evidence lacking.
Antitumor / cytotoxic: In vitro and rodent data only; no human oncology evidence.
Antibacterial: In vitro studies against oral pathogens; no clinical evidence.
Traditional respiratory use (A. racemosa): Ethnobotanically documented among numerous North American indigenous peoples; no modern clinical research available.

References

Health Conditions

Health conditions that Aralia may help support.

No conditions available.

Body Systems

Body systems that Aralia may help support.

No body systems available.